Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer

Clinical Nuclear Medicine

Volumn 42, Issue 9, 2017, Pages 704-706

  Wei, Xiao ^a   Schlenkhoff, Carl ^a   Schwarz, Bettina ^a   Essler, Markus ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

177 Lu; brain metastases; prostate cancer; PSMA; radioligand therapy

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; PSMA 617 LU 177; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; BRAIN TUMOR; DIAGNOSTIC IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGNOSIS; SECONDARY;

AGED; BRAIN NEOPLASMS; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 85024482776     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001763     Document Type: Article

References (9)

1. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
2. Braat A, Ahmadzadehfar H. Lutetium-177 labelled PSMA ligands for the treatment of metastatic castrate-resistant prostate cancer. Tijdschr Nucl Geneesk. 2016;38:1627-1634.
3. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85-90.
4. Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57: 1334-1338.
5. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrateresistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.
6. Kulkarni HR, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:97S-104S.
7. Yordanova A, Becker A, Eppard E, et al. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017. [Epub ahead of print].
8. Ahmadzadehfar H, Zimbelmann S,YordanovaA, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017. [Epub ahead of print].
9. Hatzoglou V, Patel GV, Morris MJ, et al. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging. 2014;24:161-166.